CDE Detailed Report
Disease:
Sub-Domain: Outcomes and End Points
CRF:
Sub-Domain: Outcomes and End Points
CRF:
55 results.
| CDE ID | CDE Name | Variable Name | Definition | Short Description | Additional Notes (Question Text) | Permissible Values | Description | Data Type | Disease Specific Instructions | Disease Specific Reference | Population | Classification (e.g., Core) | Version Number | Version Date | CRF Name (CRF Module / Guideline) | Sub Domain Name | Domain Name | Size | Input Restrictions | Min Value | Max Value | Measurement Type | Source | Form Set | Form | Field | Domain | CDASH Variable | CDASH Definition | CDASH Label | Controlled Terminology | Prompt | Essentiality | Question Text | CDASH imp guidance | SDTM IG target | csDSR | PhenX | Data Type | CRF Completion Inst | SDTMIG Target Var | SDTMIG Target Map | Codelist Name | PVs | Pre Pop Value | Query Display | List Style |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C60532 | Gene editing on target indel bone marrow mononuclear cell count | GnEdOnTgtIndelBMMCCt | Count of on-target indels in gene editing of bone marrow mononuclear cells (BMMC). | Count of on-target indels in gene editing of bone marrow mononuclear cells (BMMC). | BMMC On-Target Indels: | Numeric Values | Adult;Pediatric | Core | 1.00 | 2021-04-23 11:40:19.0 | Gene Product Follow-Up | Outcomes and End Points | cookie-policy |
Free-Form Entry |
|||||||||||||||||||||||||||||||||
| C60488 | Peripheral blood mononuclear cell positive for integrating viral vector percent value | PBMCPostvFrIntgrtVrlVctrPctVal | Value of the percentage of peripheral blood mononuclear cells (PBMC) positive for the integrating viral vector. | Value of the percentage of peripheral blood mononuclear cells (PBMC) positive for the integrating viral vector. | Percentage of Blood Cells Positive for Integrating Vector: PBMC | Numeric Values | Adult;Pediatric | Core | 1.00 | 2021-04-22 13:33:03.0 | Gene Product Follow-Up | Outcomes and End Points | cookie-policy |
Free-Form Entry |
0 | 100 | percent | ||||||||||||||||||||||||||||||
| C60639 | Blood CD3 depleted conversion percent value | BloodCD3DepleteConversnPctVal | Value of the percentage of conversions related to CD3 depletion in blood. | Value of the percentage of conversions related to CD3 depletion in blood. | Percent conversion | Numeric Values | Adult;Pediatric | Core | 1.00 | 2021-04-30 11:22:27.0 | Gene Product Follow-Up | Outcomes and End Points | cookie-policy |
Free-Form Entry |
0 | 100 | percent | ||||||||||||||||||||||||||||||
| C60522 | Gene editing conversion blood GPA plus lineage percent value | GnEdConvBldGPAPlsLinePctVal | Value of the percentage of gene-editing conversions in the blood GPA+ lineage. | Value of the percentage of gene-editing conversions in the blood GPA+ lineage. | Percent conversion in Specific Blood Lineages: GPA+ | Numeric Values | Adult;Pediatric | Core | 1.00 | 2021-04-23 11:20:12.0 | Gene Product Follow-Up | Outcomes and End Points | cookie-policy |
Free-Form Entry |
0 | 100 | percent | ||||||||||||||||||||||||||||||
| C60650 | Site specific nuclease gene edit on target frequency method type | SitSpcNcleasGnEdOnTgtFqMthdTyp | Type of method used for determining on-target frequency of gene editing for site-specific nucleases. | Type of method used for determining on-target frequency of gene editing for site-specific nucleases. | Method | RFLP;Sanger sequencing;Western Blot;NGS;TIDE3;Reporter gene assay;Other | Restriction fragment length polymorphism;Sanger sequencing;Western Blot;Next-generation sequencing;Tracking of Indels by Decomposition - 3;Reporter gene assay;Other | Alphanumeric | Adult;Pediatric | Core | 1.00 | 2021-04-30 11:52:35.0 | Gene Product Follow-Up | Outcomes and End Points | cookie-policy |
Single Pre-Defined Value Selected |
55 results.